close

Clinical Trials

1 2 3 192
Number of results: 3838

Excel print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2017-06-27 GKT831 (formerly GKT137831) primary biliary cholangitis (PBC) 2 Genkyotex (Switzerland) Liver diseases - Hepatic diseases
2017-06-26 givosiran (ALN-AS1) hepatic porphyrias, including acute intermittent porphyria (AIP) 1 Alnylam Pharmaceuticals (USA - MA) Rare diseases - Metabolic diseases
2017-06-26 emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) hemophilia A 3 Roche (Switzerland) Rare diseases - Genetic diseases - Hematological diseases
2017-06-26 emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) hemophilia A 3 Roche (Switzerland) Rare diseases - Genetic diseases - Hematological diseases
2017-06-26 fitusiran (SAR439774 - ALN-AT3) hemophilia A, hemophilia B with or without inhibitors 2 Alnylam Therapeutics (USA - MA), Sanofi (France) Rare diseases - Genetic diseases - Hematological diseases
2017-06-26 fitusiran (SAR439774 - ALN-AT3) hemophilia A preclinical Alnylam Pharmaceuticals (USA - MA) Hematological diseases - Genetic diseases - Rare diseases
2017-06-26 givosiran (ALN-AS1) acute hepatic porphyria Alnylam Pharmaceuticals (USA - MA) Rare diseases - Metabolic diseases
2017-06-26 ALN-F12 hereditary angioedema, prevention of thrombosis preclinical Alnylam Therapeutics (USA - MA) Rare diseases - Genetic diseases - Hematological diseases
2017-06-16 tisotumab vedotin (HuMax-TF-ADC) solid tumors (ovarian cancer, cervical cancer, endometrium cancer, bladder cancer, prostate cancer, esophageal cancer, lung cancer) 1-2 Genmab (Denmark) Cancer - Oncology
2017-06-15 OSE-127 (Effi-7) ulcerative colitis preclinical OSE Immunotherapeutics (France) Autoimmune diseases - Inflammatory diseases - Digestive diseases
2017-06-11 PQ912 Alzheimer’s Disease 2a Probiodrug (Germany) Neurodegenerative diseases
2017-06-10 MYL-1501D (biosimilar version of insulin glargin) type 1 diabetes, type 2 diabetes 3 Mylan (USA - PA) Biocon (India) Metabolic diseases
2017-06-10 ZGN-1061 patients with type 2 diabetes who are overweight or obese 1 Zafgen (USA - MA) Metabolic diseases
2017-06-10 ertugliflozin type 2 diabetes 3 Merck&Co (USA - NJ) - Pfizer (USA - NY) Metabolic diseases
2017-06-10 galcanezumab (LY2951742) episodic migraine, chronic migraine 3 Eli Lilly (USA - IN) CNS diseases - Neurological diseases
2017-06-10 Soliqua®/iGlarLixi® (single injection Lyxumia®(lixisenatide) /Lantus® (insuline glargine) combination product diabetes 3 Sanofi (France) Zealand Pharma (Denmark) Metabolic diseases
2017-06-09 Orkambi® (lumacaftor in combination with ivacaftor ) cystic fibrosis 3 Vertex Pharmaceuticals (USA - MA) Rare diseases - Genetic diseases
2017-06-09 Xilonix™ advanced colorectal cancer 3 XBiotech (USA - TX) Cancer - Oncology
2017-06-09 Orkambi® (lumacaftor in combination with ivacaftor ) children with cystic fibrosis (CF) ages 6 through 11 who have two copies of the F508del mutation 3 Vertex Pharmaceuticals (USA - MA) Rare diseases - Genetic diseases
2017-06-09 Xtandi® (enzalutamide) non metastatic castration-resistant prostate cancer 3 Medivation (USA - CA), now Pfizer (USA - NY) Astellas (Japan) Cancer - Oncology